| Autor: |
Tseretopoulou, Xanthippi, Ali, Salma R, Bryce, Jillian, Amin, Nadia, Atapattu, Navoda, Bachega, Tania A S S, Baronio, Federico, Ortolano, Rita, Birkebaek, Niels H, Bonfig, Walter, Cools, Martine, Davies, Justin H, Thomas, Tessy, Vries, Liat de, Elsedfy, Heba, Amr, Nermine H, Flueck, Christa E, Globa, Evgenia, Guran, Tulay, Yavas-Abali, Zehra |
| Předmět: |
|
| Zdroj: |
Journal of the Endocrine Society; Oct2024, Vol. 8 Issue 10, p1-8, 8p |
| Abstrakt: |
Background It is unclear whether targeted monitoring of acute adrenal insufficiency (AI) related adverse events (AE) such as sick day episodes (SDEs) and hospitalization rate in congenital adrenal hyperplasia (CAH) is associated with a change in the occurrence of these events. Aim Study temporal trends of AI related AE in the I-CAH Registry. Methods In 2022, data on the occurrence of AI-related AE in children aged <18 years with 21-hydroxylase deficiency CAH were compared to data collected in 2019. Results In 2022, a total of 513 children from 38 centers in 21 countries with a median of 8 children (range 1-58) per center had 2470 visits evaluated over a 3-year period (2019-2022). The median SDE per patient year in 2022 was 0 (0-2.5) compared to 0.3 (0-6) in 2019 (P =.01). Despite adjustment for age, CAH phenotype and duration of study period, a difference in SDE rate was still apparent between the 2 cohorts. Of the 38 centers in the 2022 cohort, 21 had also participated in 2019 and a reduction in SDE rate was noted in 13 (62%), an increase was noted in 3 (14%), and in 5 (24%) the rate remained the same. Of the 474 SDEs reported in the 2022 cohort, 103 (22%) led to hospitalization compared to 299 of 1099 SDEs (27%) in the 2019 cohort (P =.02). Conclusion The I-CAH Registry can be used for targeted monitoring of important clinical benchmarks in CAH. However, changes in reported benchmarks need careful interpretation and longer-term monitoring. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
